Does He Stop Before You Try to Conceive?

The short version

Two people in one house, one of them on a GLP-1, and a plan to start trying. The rules for her are written down. The rules for him are not written down anywhere, by anyone.

That asymmetry is the entire answer, and most of the confusion in this decision comes from people quietly assuming his rules must look like hers.

Her side: the guidance exists

An international expert group published consensus guidance in 2026 on incretin-based medications and women's reproductive health¹. It states plainly that pregnancy while taking these drugs is contraindicated because the risk of teratogenicity is unknown, and says the same of breastfeeding.

The group screened the literature and built its recommendations from 34 included articles — 11 randomized trials, nine observational studies, two pharmacovigilance reviews, nine case reports or series, two animal studies and one ex vivo study — covering contraception, preconception, nutrition, pregnancy monitoring, lactation and longer-term outcomes. Notably, no study reported an increase in congenital anomalies, though the exposed-pregnancy samples are small and only three studies covered exposure throughout pregnancy.

Thin in places, but it exists. Someone has looked, and there is a recommendation to follow. That is covered in more detail on can you take Zepbound while pregnant.

His side: there is no guidance, because there is no research

Every one of those 34 articles is about maternal exposure. The consensus is titled for women and scoped to women. Search the literature for the father's side and what comes back is the same set of studies about mothers.

No study has asked whether a man taking a GLP-1 at the time of conception affects the pregnancy or the child.

That is a finding, not a gap to be smoothed over with a confident-sounding paragraph. Anyone who tells you the answer — in either direction — is telling you something the evidence does not contain.

What is actually known about his side

The trap in "he should stop just to be safe"

Stopping sounds like the cautious choice, and it is worth seeing why it is not a neutral one.

Coming off a GLP-1 commonly means regaining weight. Regain is the specific thing that erased the sperm improvement at one year in the trial above — the men who maintained the loss kept the gain, and the men who regained lost it. So stopping trades an unmeasured, hypothetical benefit for a fairly well-measured cost.

There is also a timing problem that catches people out. Sperm take roughly two to three months to be made, so a sample collected a few weeks after he stops is still reporting on the period when he was taking it. Stopping the month before you start trying does not produce a clean slate; it produces the same slate plus some weight regain.

None of that means he should stay on it. It means "stop to be safe" is a decision with two sides, not an obviously conservative default.

What to actually ask

• Ask the prescriber directly whether there is paternal data. There is not, as of now — but you want to hear that from the person managing the drug rather than from a page.
• Ask why he is on it. A GLP-1 taken for type 2 diabetes and one taken for 15 pounds are not the same decision to interrupt.
• Ask what stopping would mean for his weight, and whether he has a maintenance plan that is not the drug.
• Ask whether the timeline is actually his. If the two of you have a window, hers is usually the one the calendar should be built around.
• Do not apply her rule to him. Hers comes from a real recommendation about a real exposure. His does not exist yet, and borrowing hers is not caution — it is a guess wearing caution's clothes.

Where this sits

Her contraindication in pregnancy: established guidance, from a 2026 international consensus, though built on thin exposure data.

Weight loss improving his sperm count and concentration: moderate — one preregistered semen analysis inside a randomized controlled trial.

Maintenance mattering more than which strategy maintains it: moderate, same trial.

Paternal exposure at conception: no evidence at all. Not weak evidence. None.